by Mike Regan | Sep 23, 2022 | Comp Table & Market Commentary, Company Analysis, Data & Analysis, Extract, Macro, Thematic Research
As valuations and liquidity have declined since the first quarter 2021 (when the industry raised over $3 billion in equity), debt has become a go-to source of financing. What is the leverage in cannabis? It may be higher than you think. There are also debates on if...
by Mike and Colin | Feb 23, 2022 | Company Analysis, Earnings Report, Extract
3Q Earnings Reviews from the Weekly Extract Archive for Extract Subs As we enter 4Q21 earnings season, we have consolidated the 29 cannabis company earnings reports from the 3Q21 earnings season published in the Extract Archive into a single note to help investors...
by Mike and Colin | Jan 16, 2022 | Extract
Welcome to the Weekly Extract, parsing key information out of the week’s cannabis headlines. You can sign up to receive the Weekly Extract here. Each week you will receive an email of about ~3,000 words of real-time analysis and key takeaways of the week’s...
by Mike and Colin | Dec 20, 2021 | Extract
Welcome to the Weekly Extract, parsing key information out of the week’s cannabis headlines. This week’s Extract covers …. Recently Published What’s left of Curaleaf’s $425m new debt after refis? State & Internationa News New York...
by Mike and Colin | Dec 18, 2021 | Company Analysis
Since this was originally published, Curaleaf upsized the deal by another $50 million, so add simplistically $50 million to all figures below. Curaleaf just raised $425 million of notes due 2026 at 8%; the size and access to capital is impressive in itself. The stated...
